 Analgesics
|
Anesthetics
|
Anti-Addiction/Substance Abuse Treatment Agents
|
Antibacterials
|
Anticonvulsants
|
Antidementia Agents
|
Antidepressants
|
Antiemetics
|
Antifungals
|
Antigout Agents
|
Antimigraine Agents
|
Antimyasthenic Agents
|
Antimycobacterials
|
 Antineoplastics
|
Alkylating Agents
|
Antiandrogens
|
Antiestrogens/Modifiers
|
Antimetabolites
|
Aromatase Inhibitors
|
Immunomodulatory Agents
|
Molecular Target Inhibitors
|
Monoclonal Antibody/Antibody-Drug Conjugate
|
Retinoids
|
Antineoplastic Adjuncts/Mitigators
|
Antineoplastics, Other
|
Aldesleukin
|
Arsenic Trioxide
|
Asparaginase Erwinia (Recombinant)
|
Asparaginase Erwinia chrysanthemi
|
Bleomycin [DG:DG00705]
|
Cabazitaxel [DG:DG00695]
|
Calaspargase pegol
|
Cedazuridine/ Decitabine
|
Dactinomycin
|
Daunorubicin/ Cytarabine
|
Degarelix [DG:DG00736]
|
Docetaxel [DG:DG00694]
|
Eribulin
|
Goserelin [DG:DG00731]
|
Hydroxyurea
|
Ixabepilone
|
Lanreotide
|
Leucovorin [DG:DG02073]
|
Leuprolide [DG:DG00730]
|
Levoleucovorin [DG:DG03003]
|
Mitomycin
|
Mitotane
|
Mitoxantrone [DG:DG00701]
|
 D02166 Mitoxantrone hydrochloride (JAN/USP)
|
Niraparib/ Abiraterone Acetate
|
Octreotide [DG:DG00501]
|
Omacetaxine Mepesuccinate
|
Paclitaxel [DG:DG01430]
|
Pegaspargase
|
Relugolix
|
Sipuleucel-T/ Lactated Ringers
|
Talimogene Laherparepvec
|
Tebentafusp
|
Tipiracil/ Trifluridine
|
Triptorelin [DG:DG00732]
|
Uridine Triacetate
|
Ziv-aflibercept
|
Anti-Obesity Agents
|
Antiparasitics
|
Antiparkinson Agents
|
Antipsychotics
|
Antispasticity Agents
|
Antivirals
|
Anxiolytics
|
Bipolar Agents
|
Blood Glucose Regulators
|
Blood Products and Modifiers
|
Cardiovascular Agents
|
Central Nervous System Agents
|
Amyotrophic Lateral Sclerosis (ALS) Agents
|
Attention Deficit Hyperactivity Disorder Agents, Amphetamines
|
Attention Deficit Hyperactivity Disorder Agents, Non-amphetamines
|
Fibromyalgia Agents
|
Multiple Sclerosis Agents
|
Dimethyl Fumarate
|
Diroximel Fumarate
|
Monomethyl Fumarate
|
Dalfampridine
|
Teriflunomide
|
Interferon Beta-1a [DG:DG01751]
|
Interferon Beta-1b [DG:DG01751]
|
Peginterferon Beta-1a
|
Fingolimod [DG:DG00741]
|
Ozanimod [DG:DG02827]
|
Siponimod [DG:DG03018]
|
Alemtuzumab
|
Cladribine
|
Glatiramer
|
Mitoxantrone [DG:DG00701]
|
D02166 Mitoxantrone hydrochloride (JAN/USP)
|
Natalizumab
|
Ocrelizumab
|
Ponesimod
|
Ublituximab
|
Central Nervous System, Other
|
Contraceptives
|
Dental and Oral Agents
|
Dermatological Agents
|
Electrolytes/Minerals/Metals/Vitamins
|
Gastrointestinal Agents
|
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
|
Genitourinary Agents
|
Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
|
Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary)
|
Hormonal Agents, Stimulant/Replacement/Modifying (Prostaglandins)
|
Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
|
Hormonal Agents, Stimulant/Replacement/Modifying (Thyroid)
|
Hormonal Agents, Suppressant (Pituitary)
|
Hormonal Agents, Suppressant (Thyroid)
|
Immunological Agents
|
Infertility Agents
|
Inflammatory Bowel Disease Agents
|
Metabolic Bone Disease Agents
|
Ophthalmic Agents
|
Otic Agents
|
Respiratory Tract/Pulmonary Agents
|
Sexual Disorder Agents
|
Skeletal Muscle Relaxants
|
Sleep Disorder Agents
|
USP Drug Classification